Exabis Library
Welcome to the e-CCO Library!
DOP17: Evaluating segmental healing with the modified Mayo endoscopic score (MMES) has a clear additional value in predicting long-term outcome in patients with Ulcerative Colitis: Results from a prospective cohort study
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP17: HIV infection is associated with a less aggressive phenotype of inflammatory bowel disease. A multicenter study based on the ENEIDA registry.
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 2:22 PM
DOP17: HIV infection is associated with a less aggressive phenotype of inflammatory bowel disease. A multicenter study based on the ENEIDA registry.
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP17: Identification of biomarkers and mechanistic insight for upadacitinib in Ulcerative Colitis: Analysis of serum inflammatory mediators in the phase 2b U-ACHIEVE study
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 5:40 PM
DOP17: Identification of biomarkers and mechanistic insight for upadacitinib in Ulcerative Colitis: Analysis of serum inflammatory mediators in the phase 2b U-ACHIEVE study
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
DOP17: In high-risk Crohn’s Disease patients, anastomosis configuration types have similar rates of endoscopic recurrence
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP17: Tofacitinib versus Vedolizumab Among Bio-naïve Patients With Ulcerative Colitis: A Real-World Propensity-Weighted Comparison
2024
ECCO'24 Stockholm
Tuesday, 30 April 2024, 5:03 PM
DOP18 Impact of adherence to anti-tumour necrosis factor therapy on clinical outcomes in Crohn’s disease: A nationwide population-based study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP18: Advanced optical diagnosis technology for assessment of endoscopic and histological remission in Ulcerative Colitis: A systematic review and meta-analysis
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP18: Brain structural correlates of fatigue in active and quiescent Crohn's Disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP18: Brain structural correlates of fatigue in active and quiescent Crohn’s Disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 2:22 PM
DOP18: Efficacy of risankizumab versus ustekinumab by baseline Crohn’s Disease location: post-hoc analysis of the SEQUENCE head-to-head trial
2024
ECCO'24 Stockholm
Tuesday, 30 April 2024, 5:03 PM
DOP18: Impact of adherence to anti- tumor necrosis factor therapy on clinical outcomes in Crohn's Disease: A nationwide population-based study
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 5:40 PM
DOP18: Impact of adherence to anti- tumor necrosis factor therapy on clinical outcomes in Crohn's Disease: A nationwide population-based study
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
DOP18: OSM neutralisation in IBD mucosal explant cultures reduces pro-inflammatory cytokine production
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
DOP18: OSM neutralisation in IBD mucosal explant cultures reduces pro-inflammatory cytokine production
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP18: UCEIS is associated with PRO2, partial Mayo and SCCAI remission in UC: Final results from a prospective study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP19 Real-world healthcare resource utilisation among patients with inflammatory bowel disease administered vedolizumab for 6 months
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP19: High dimensional profiling of IL-23-responsive cells revealed molecular signatures that predict response to anti-IL-23 therapy in patients with Crohn’s Disease
2024
ECCO'24 Stockholm
Tuesday, 30 April 2024, 5:03 PM
DOP19: Incidence and initial disease presentation of inflammatory bowel diseases in Denmark: findings from a Copenhagen IBD Inception Cohort Study (IBD Prognosis Study)
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 2:22 PM